RU2009145541A - Терапевтические соединения - Google Patents
Терапевтические соединения Download PDFInfo
- Publication number
- RU2009145541A RU2009145541A RU2009145541/04A RU2009145541A RU2009145541A RU 2009145541 A RU2009145541 A RU 2009145541A RU 2009145541/04 A RU2009145541/04 A RU 2009145541/04A RU 2009145541 A RU2009145541 A RU 2009145541A RU 2009145541 A RU2009145541 A RU 2009145541A
- Authority
- RU
- Russia
- Prior art keywords
- formula
- animal
- stereoisomer
- compound according
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/02—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
- C07C39/06—Alkylated phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/20—Diazonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/001—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain
- C07C37/003—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by modification in a side chain by hydrogenation of an unsaturated part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
- C07C37/045—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis by substitution of a group bound to the ring by nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/01—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
- C07C37/055—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C37/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
- C07C37/68—Purification; separation; Use of additives, e.g. for stabilisation
- C07C37/86—Purification; separation; Use of additives, e.g. for stabilisation by treatment giving rise to a chemical modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/26—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
- C07C39/27—Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
1. (-)-стереоизомер формулы (I) ! ! в которой X является H или F; или его соль, или его пролекарство. ! 2. Соединение по п.1, которое является (-)-стереоизомером формулы (I), или его фармацевтически приемлемой солью, или его пролекарством. ! 3. Соединение по п.2, которое является (-)-стереоизомером формулы (I) или его фармацевтически приемлемой солью. ! 4. Соединение по любому из пп.1-3, в котором X является H. ! 5. Фармацевтическая композиция, содержащая соединение по любому из пп.2-4 и фармацевтически приемлемый носитель. ! 6. Фармацевтическая композиция по п.5, которая включена в состав для внутривенного введения. ! 7. Фармацевтическая композиция по п.6, которая включена в состав как липидная эмульсия. ! 8. Способ индуцирования или поддержания общей анестезии у животного, включающий введение животному эффективного количества (-)-стереоизомера формулы (I) ! ! в которой X является H или F; или его фармацевтически приемлемой соли или его пролекарства. ! 9. Способ по п.8, в котором X является H. ! 10. Способ по п.8, включающий введение животному эффективного количества (-)-стереоизомера формулы (I), в которой X является H, или его фармацевтически приемлемой соли. ! 11. Способ промотирования обезболивания животного, включающий введение животному эффективного количества (-)-стереоизомера формулы (I) ! ! в которой X является H или F; или его фармацевтически приемлемой соли или его пролекарства. ! 12. Способ по п.11, в котором X является H. ! 13. Способ по п.11, включающий введение животному эффективного количества (-)-стереоизомера формулы (I), в которой X является H, или его фармацевтически приемлемой соли. ! 14. Соединение по пп.2-4 для применения в лекарственной терапии. ! 15
Claims (19)
2. Соединение по п.1, которое является (-)-стереоизомером формулы (I), или его фармацевтически приемлемой солью, или его пролекарством.
3. Соединение по п.2, которое является (-)-стереоизомером формулы (I) или его фармацевтически приемлемой солью.
4. Соединение по любому из пп.1-3, в котором X является H.
5. Фармацевтическая композиция, содержащая соединение по любому из пп.2-4 и фармацевтически приемлемый носитель.
6. Фармацевтическая композиция по п.5, которая включена в состав для внутривенного введения.
7. Фармацевтическая композиция по п.6, которая включена в состав как липидная эмульсия.
9. Способ по п.8, в котором X является H.
10. Способ по п.8, включающий введение животному эффективного количества (-)-стереоизомера формулы (I), в которой X является H, или его фармацевтически приемлемой соли.
12. Способ по п.11, в котором X является H.
13. Способ по п.11, включающий введение животному эффективного количества (-)-стереоизомера формулы (I), в которой X является H, или его фармацевтически приемлемой соли.
14. Соединение по пп.2-4 для применения в лекарственной терапии.
15. Соединение по любому из пп.2-4 для индуцирования или поддержания общей анестезии у животного.
16. Соединение по любому из пп.2-4 для промотирования обезболивания у животного.
17. Способ получения соединения по любому из пп.1-4, который включает
(a) гидролиз диастереоизомера (-)-2-втор-бутил-6-изопропилфенилового эфира карбаминовой кислоты формулы (II)
в которой R1 представляет хиральную аминогруппу;
(b) диазотирование соответствующего (-)-2-втор-бутил-6-изопропил анилина формулы
или
(с) восстановление соответствующего 2-(1-метилаллил)-6-изопропилфенола формулы
с последующим, если необходимо, образованием свободного фенола, или его соли, или его пролекарства.
19. Диастереоизомер по п.18, в котором R1 является (R)-1-арилэтиламиногруппой.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92834507P | 2007-05-09 | 2007-05-09 | |
US92841607P | 2007-05-09 | 2007-05-09 | |
US60/928,345 | 2007-05-09 | ||
US60/928,416 | 2007-05-09 | ||
PCT/US2008/063088 WO2008141099A1 (en) | 2007-05-09 | 2008-05-08 | Therapeutic compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2009145541A true RU2009145541A (ru) | 2011-06-20 |
RU2470907C2 RU2470907C2 (ru) | 2012-12-27 |
Family
ID=39619201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2009145541/04A RU2470907C2 (ru) | 2007-05-09 | 2008-05-08 | Терапевтические соединения |
Country Status (18)
Country | Link |
---|---|
US (3) | US8173849B2 (ru) |
EP (2) | EP2392559A1 (ru) |
JP (1) | JP2010526827A (ru) |
KR (1) | KR20100017435A (ru) |
CN (1) | CN101687746A (ru) |
AT (1) | ATE540010T1 (ru) |
AU (1) | AU2008251484A1 (ru) |
BR (1) | BRPI0811284A2 (ru) |
CA (1) | CA2685813A1 (ru) |
DK (1) | DK2152651T3 (ru) |
ES (1) | ES2380824T3 (ru) |
HK (1) | HK1138830A1 (ru) |
IL (1) | IL201735A0 (ru) |
MX (1) | MX2009012125A (ru) |
MY (1) | MY147215A (ru) |
RU (1) | RU2470907C2 (ru) |
WO (1) | WO2008141099A1 (ru) |
ZA (1) | ZA201007602B (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2146946T3 (pl) | 2007-05-09 | 2011-04-29 | Pharmacofore Inc | (-)-Stereoizomer 2,6-di-sec-butylofenolu i jego analogi |
US20120283335A1 (en) * | 2008-05-12 | 2012-11-08 | Jenkins Thomas E | Analogs of Propofol, Preparation Thereof and Use as Anesthetics |
CN102085185B (zh) * | 2010-12-07 | 2013-04-24 | 西安力邦制药有限公司 | 无痛和低注射刺激的新型丙泊酚脂肪乳制剂配方和制备方法 |
CN102603488B (zh) * | 2012-03-06 | 2017-01-04 | 云南龙海天然植物药业有限公司 | 一种制备高纯度丙泊酚的新方法 |
CN102731265B (zh) * | 2012-06-12 | 2014-12-10 | 四川百利药业有限责任公司 | 一种高纯度丙泊酚的制备方法 |
EP2915801B1 (en) * | 2012-11-02 | 2018-07-04 | Sumitomo Chemical Company, Limited | Production method for racemate of compound |
CN104649867B (zh) * | 2013-11-21 | 2017-02-15 | 辽宁药联制药有限公司 | 一种丙泊酚的制备方法 |
CN105384604B (zh) * | 2014-08-22 | 2019-07-05 | 四川海思科制药有限公司 | 一种异丙基苯酚衍生物及其制备方法 |
CN105384608B (zh) * | 2014-08-22 | 2019-08-16 | 四川海思科制药有限公司 | 一种异丙基苯酚衍生物及其制备方法 |
CN105384607B (zh) * | 2014-08-22 | 2019-08-16 | 四川海思科制药有限公司 | 一种异丙基苯酚衍生物及其制备方法 |
EA035649B1 (ru) * | 2014-09-04 | 2020-07-21 | Сычуань Хайско Фармасьютикал Ко., Лтд. | Применение агента, активирующего рецептор гамк, для получения седативного и анестезирующего лекарственного средства |
CN105820040B (zh) * | 2015-01-22 | 2018-07-24 | 四川海思科制药有限公司 | 一种异丙基苯酚衍生物及其制备方法 |
CN106278947B (zh) * | 2015-05-19 | 2020-03-06 | 四川海思科制药有限公司 | 苯酚衍生物的晶型及其制备方法 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2747982A (en) | 1955-05-11 | 1956-05-29 | Dow Chemical Co | Method and composition for the control of the growth of vegetation |
GB1472793A (en) | 1974-03-28 | 1977-05-04 | Ici Ltd | Pharmaceutical compositions |
US4798846A (en) | 1974-03-28 | 1989-01-17 | Imperial Chemical Industries Plc | Pharmaceutical compositions |
SU1525139A1 (ru) * | 1987-11-10 | 1989-11-30 | Куйбышевский политехнический институт им.В.В.Куйбышева | Способ получени о-втор-бутилфенола |
ES2087019B1 (es) * | 1994-02-08 | 1997-03-16 | Bobel246 S L | Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa. |
US5731355A (en) | 1994-03-22 | 1998-03-24 | Zeneca Limited | Pharmaceutical compositions of propofol and edetate |
GB9405593D0 (en) | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
US6254853B1 (en) | 1998-05-08 | 2001-07-03 | Vyrex Corporation | Water soluble pro-drugs of propofol |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
ATE267586T1 (de) | 1999-02-18 | 2004-06-15 | Supergen Inc | An phosphocholin gebundene prodrug-derivate |
US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US6362234B1 (en) | 2000-08-15 | 2002-03-26 | Vyrex Corporation | Water-soluble prodrugs of propofol for treatment of migrane |
US20020099013A1 (en) | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
WO2002044324A2 (en) | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
WO2002074200A1 (en) * | 2001-03-20 | 2002-09-26 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
HU229293B1 (hu) | 2001-12-28 | 2013-10-28 | Eisai Inc | Propofol vízoldható elõgyógyszerét tartalmazó vizes alapú gyógyászati készítmények |
US7035343B2 (en) | 2002-01-31 | 2006-04-25 | Qualcomm Inc. | Closed loop transmit diversity antenna verification using trellis decoding |
EP1485082A4 (en) | 2002-02-19 | 2009-12-30 | Xenoport Inc | PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS |
BG65734B1 (bg) | 2002-02-22 | 2009-09-30 | Био Терапютикс - Еоод | Течен мукоадхезивен фармацевтичен състав |
KR20070087004A (ko) | 2002-04-08 | 2007-08-27 | 엠쥐아이 쥐피, 아이엔씨. | 프로포폴의 수용성 프로드럭을 함유하는 약제학적 조성물및 그것을 투여하는 방법 |
DE20215415U1 (de) | 2002-10-08 | 2004-02-26 | Biotechnologie Gesellschaft Mittelhessen Mbh | Wasserlösliche Medikamentenvorstufen von Propofol |
DE60323756D1 (de) | 2002-10-08 | 2008-11-06 | Fresenius Kabi De Gmbh | Pharmazeutisch aktive oligosaccharid-conjugate |
ZA200504940B (en) | 2003-01-28 | 2006-09-27 | Xenoport Inc | Amino acid derived prodrugs of propofol, compositions and uses thereof |
AU2003901815A0 (en) | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
WO2005023204A2 (en) | 2003-09-09 | 2005-03-17 | Xenoport, Inc. | Aromatic prodrugs of propofol, compositions and uses thereof |
US20070043121A1 (en) * | 2003-09-29 | 2007-02-22 | Brown Milton L | Discovery of novel soluble crystalline anesthetics |
WO2006017351A1 (en) | 2004-07-12 | 2006-02-16 | Xenoport, Inc. | Prodrugs of propofol, compositions and uses thereof |
EP1791521A4 (en) | 2004-09-17 | 2009-10-21 | Eisai Corp North America | METHODS OF ADMINISTERING PROPOFOL PROMOTERS WITH WATER SOLUBLE |
WO2006071995A1 (en) | 2004-12-23 | 2006-07-06 | Xenoport, Inc. | Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof |
DE102005033496A1 (de) * | 2005-07-19 | 2007-01-25 | Bayer Healthcare Ag | Desinfektionsmittel |
CA2632561C (en) * | 2005-12-19 | 2015-01-27 | The University Of Liverpool | Substituted propofol derivatives as analgesics |
US7535698B2 (en) | 2006-03-07 | 2009-05-19 | Panasonic Corporation | Case, portable information equipment using the same and manufacturing method of the case |
US7731356B1 (en) | 2006-07-24 | 2010-06-08 | Daniel Ayers Gilbert | Hanging eyeglasses |
-
2008
- 2008-05-08 WO PCT/US2008/063088 patent/WO2008141099A1/en active Application Filing
- 2008-05-08 AT AT08769340T patent/ATE540010T1/de active
- 2008-05-08 CN CN200880015398A patent/CN101687746A/zh active Pending
- 2008-05-08 CA CA002685813A patent/CA2685813A1/en not_active Abandoned
- 2008-05-08 MY MYPI20094593A patent/MY147215A/en unknown
- 2008-05-08 DK DK08769340.4T patent/DK2152651T3/da active
- 2008-05-08 KR KR1020097024778A patent/KR20100017435A/ko not_active Application Discontinuation
- 2008-05-08 MX MX2009012125A patent/MX2009012125A/es active IP Right Grant
- 2008-05-08 ES ES08769340T patent/ES2380824T3/es active Active
- 2008-05-08 BR BRPI0811284-3A2A patent/BRPI0811284A2/pt not_active IP Right Cessation
- 2008-05-08 RU RU2009145541/04A patent/RU2470907C2/ru not_active IP Right Cessation
- 2008-05-08 AU AU2008251484A patent/AU2008251484A1/en not_active Abandoned
- 2008-05-08 US US12/596,711 patent/US8173849B2/en not_active Expired - Fee Related
- 2008-05-08 JP JP2010507667A patent/JP2010526827A/ja active Pending
- 2008-05-08 EP EP11177818A patent/EP2392559A1/en not_active Withdrawn
- 2008-05-08 EP EP08769340A patent/EP2152651B1/en active Active
-
2009
- 2009-10-25 IL IL201735A patent/IL201735A0/en unknown
-
2010
- 2010-06-04 HK HK10105524.2A patent/HK1138830A1/xx not_active IP Right Cessation
- 2010-10-25 ZA ZA2010/07602A patent/ZA201007602B/en unknown
-
2012
- 2012-04-02 US US13/437,802 patent/US8350097B2/en not_active Expired - Fee Related
- 2012-12-03 US US13/692,853 patent/US20130217783A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101687746A (zh) | 2010-03-31 |
MY147215A (en) | 2012-11-14 |
US8350097B2 (en) | 2013-01-08 |
EP2152651B1 (en) | 2012-01-04 |
BRPI0811284A2 (pt) | 2015-01-20 |
US20100249246A1 (en) | 2010-09-30 |
EP2152651A1 (en) | 2010-02-17 |
HK1138830A1 (en) | 2010-09-03 |
MX2009012125A (es) | 2010-02-18 |
KR20100017435A (ko) | 2010-02-16 |
US8173849B2 (en) | 2012-05-08 |
IL201735A0 (en) | 2010-06-16 |
ZA201007602B (en) | 2012-08-29 |
CA2685813A1 (en) | 2008-11-20 |
AU2008251484A1 (en) | 2008-11-20 |
EP2392559A1 (en) | 2011-12-07 |
DK2152651T3 (da) | 2012-04-10 |
RU2470907C2 (ru) | 2012-12-27 |
US20120196939A1 (en) | 2012-08-02 |
ATE540010T1 (de) | 2012-01-15 |
ES2380824T3 (es) | 2012-05-18 |
JP2010526827A (ja) | 2010-08-05 |
US20130217783A1 (en) | 2013-08-22 |
WO2008141099A1 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2009145541A (ru) | Терапевтические соединения | |
JP2010526827A5 (ru) | ||
US8293253B2 (en) | Compositions for controlled delivery of pharmaceutically active compounds | |
AU2014340303B2 (en) | Tyrosine hydroxylase inhibitors for treating intestinal hyperpermeability | |
JP2013545730A5 (ru) | ||
JP2005529840A5 (ru) | ||
RU2007147420A (ru) | Органические соединения для лечения воспалительных или аллергических состояний | |
RU2009145537A (ru) | Терапевтические соединения | |
JP2003502308A5 (ru) | ||
RU2007138582A (ru) | Пероральные дозированные формы производных гемцитабина | |
RU2011147201A (ru) | Регероматические и ароматические пиперазинил ацетидинил амиды как моноцилглицероловые ингибиторы липазы | |
US8883853B2 (en) | N-substituted benzenepropanamide or benzenepropenamide derivatives for use in the treatment of pain and inflammation | |
RU2014119711A (ru) | Трициклические соединения, композиции, содержащие указанные соединения, и их применения | |
JP2017533964A5 (ru) | ||
CN1503667A (zh) | 用于预防或治疗神经变性疾病的氨基甲酸酯化合物 | |
JP2010526826A5 (ru) | ||
KR20160005356A (ko) | 방사선완화 약제학적 제형 | |
RU2015104097A (ru) | Соединения мочевины и их применение в качестве ингибиторов ферментов | |
EP2150550A4 (en) | NOVEL CARBAMOYLOXY ARYL ALKANE ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING SAID COMPOUND | |
JP2014504648A5 (ru) | ||
RU2007107850A (ru) | Способы повышения биологической доступности ингибитора ренина | |
EA201070603A1 (ru) | Лекарственное средство, активное в отношении невропатической боли | |
RU2008138749A (ru) | Производные камптотецина и их применение | |
RU2019102757A (ru) | Производные этинила | |
RU2017137960A (ru) | Применение тиаоксосоединений для уменьшения содержания аро сз |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20130509 |